vs
SANFILIPPO JOHN B & SON INC（JBSS）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
SANFILIPPO JOHN B & SON INC的季度营收约是Ultragenyx Pharmaceutical Inc.的1.5倍（$314.8M vs $207.3M），SANFILIPPO JOHN B & SON INC净利率更高（5.7% vs -62.0%，领先67.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 4.6%），SANFILIPPO JOHN B & SON INC自由现金流更多（$40.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.6%）
John B. Sanfilippo & Son Inc.（股票代码JBSS）是美国领先的坚果零食加工分销商，主营树坚果、花生、果干及增值零食产品，为北美零售、餐饮及工业原料客户提供自有品牌和贴牌产品。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
JBSS vs RARE — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $314.8M | $207.3M |
| 净利润 | $18.0M | $-128.6M |
| 毛利率 | 18.8% | — |
| 营业利润率 | 8.3% | -54.7% |
| 净利率 | 5.7% | -62.0% |
| 营收同比 | 4.6% | 25.9% |
| 净利润同比 | 32.1% | 3.5% |
| 每股收益（稀释后） | $1.53 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $314.8M | $207.3M | ||
| Q3 25 | $298.7M | $159.9M | ||
| Q2 25 | $269.1M | $166.5M | ||
| Q1 25 | $260.9M | $139.3M | ||
| Q4 24 | $301.1M | $164.6M | ||
| Q3 24 | $276.2M | $139.5M | ||
| Q2 24 | $269.6M | $147.0M | ||
| Q1 24 | $271.9M | $108.8M |
| Q4 25 | $18.0M | $-128.6M | ||
| Q3 25 | $18.7M | $-180.4M | ||
| Q2 25 | $13.5M | $-115.0M | ||
| Q1 25 | $20.2M | $-151.1M | ||
| Q4 24 | $13.6M | $-133.2M | ||
| Q3 24 | $11.7M | $-133.5M | ||
| Q2 24 | $10.0M | $-131.6M | ||
| Q1 24 | $13.5M | $-170.7M |
| Q4 25 | 18.8% | — | ||
| Q3 25 | 18.1% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 21.4% | — | ||
| Q4 24 | 17.4% | — | ||
| Q3 24 | 16.9% | — | ||
| Q2 24 | 18.5% | — | ||
| Q1 24 | 18.1% | — |
| Q4 25 | 8.3% | -54.7% | ||
| Q3 25 | 9.0% | -106.9% | ||
| Q2 25 | 7.5% | -64.8% | ||
| Q1 25 | 10.8% | -102.6% | ||
| Q4 24 | 6.4% | -74.3% | ||
| Q3 24 | 6.2% | -94.6% | ||
| Q2 24 | 5.4% | -79.1% | ||
| Q1 24 | 6.7% | -151.9% |
| Q4 25 | 5.7% | -62.0% | ||
| Q3 25 | 6.3% | -112.8% | ||
| Q2 25 | 5.0% | -69.0% | ||
| Q1 25 | 7.7% | -108.5% | ||
| Q4 24 | 4.5% | -80.9% | ||
| Q3 24 | 4.2% | -95.7% | ||
| Q2 24 | 3.7% | -89.5% | ||
| Q1 24 | 5.0% | -156.8% |
| Q4 25 | $1.53 | $-1.28 | ||
| Q3 25 | $1.59 | $-1.81 | ||
| Q2 25 | $1.15 | $-1.17 | ||
| Q1 25 | $1.72 | $-1.57 | ||
| Q4 24 | $1.16 | $-1.34 | ||
| Q3 24 | $1.00 | $-1.40 | ||
| Q2 24 | $0.85 | $-1.52 | ||
| Q1 24 | $1.15 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4M | $421.0M |
| 总债务越低越好 | $28.8M | — |
| 股东权益账面价值 | $370.1M | $-80.0M |
| 总资产 | $617.7M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.08× | — |
8季度趋势，按日历期对齐
| Q4 25 | $2.4M | $421.0M | ||
| Q3 25 | $714.0K | $202.5M | ||
| Q2 25 | $585.0K | $176.3M | ||
| Q1 25 | $1.3M | $127.1M | ||
| Q4 24 | $336.0K | $174.0M | ||
| Q3 24 | $442.0K | $150.6M | ||
| Q2 24 | $484.0K | $480.7M | ||
| Q1 24 | $377.0K | $112.3M |
| Q4 25 | $28.8M | — | ||
| Q3 25 | $29.8M | — | ||
| Q2 25 | $14.6M | — | ||
| Q1 25 | $5.8M | — | ||
| Q4 24 | $6.0M | — | ||
| Q3 24 | $6.2M | — | ||
| Q2 24 | $6.4M | — | ||
| Q1 24 | $6.6M | — |
| Q4 25 | $370.1M | $-80.0M | ||
| Q3 25 | $362.8M | $9.2M | ||
| Q2 25 | $360.7M | $151.3M | ||
| Q1 25 | $346.6M | $144.2M | ||
| Q4 24 | $325.6M | $255.0M | ||
| Q3 24 | $310.8M | $346.8M | ||
| Q2 24 | $322.6M | $432.4M | ||
| Q1 24 | $321.8M | $140.3M |
| Q4 25 | $617.7M | $1.5B | ||
| Q3 25 | $598.7M | $1.2B | ||
| Q2 25 | $597.6M | $1.3B | ||
| Q1 25 | $590.0M | $1.3B | ||
| Q4 24 | $545.3M | $1.5B | ||
| Q3 24 | $519.4M | $1.5B | ||
| Q2 24 | $515.6M | $1.6B | ||
| Q1 24 | $491.9M | $1.3B |
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.02× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | 0.02× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $40.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 12.7% | -48.6% |
| 资本支出强度资本支出/营收 | 7.1% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.48× | — |
| 过去12个月自由现金流最近4个季度 | $32.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $62.5M | $-99.8M | ||
| Q3 25 | $32.1M | $-91.4M | ||
| Q2 25 | $36.5M | $-108.3M | ||
| Q1 25 | $-25.9M | $-166.5M | ||
| Q4 24 | $11.0M | $-79.3M | ||
| Q3 24 | $8.9M | $-67.0M | ||
| Q2 24 | $35.2M | $-77.0M | ||
| Q1 24 | $5.3M | $-190.7M |
| Q4 25 | $40.0M | $-100.8M | ||
| Q3 25 | $7.3M | $-92.7M | ||
| Q2 25 | $23.0M | $-110.7M | ||
| Q1 25 | $-37.6M | $-167.8M | ||
| Q4 24 | $-2.7M | $-79.5M | ||
| Q3 24 | $-3.0M | $-68.6M | ||
| Q2 24 | $24.4M | $-79.0M | ||
| Q1 24 | $-1.3M | $-193.9M |
| Q4 25 | 12.7% | -48.6% | ||
| Q3 25 | 2.4% | -58.0% | ||
| Q2 25 | 8.6% | -66.5% | ||
| Q1 25 | -14.4% | -120.5% | ||
| Q4 24 | -0.9% | -48.3% | ||
| Q3 24 | -1.1% | -49.2% | ||
| Q2 24 | 9.0% | -53.7% | ||
| Q1 24 | -0.5% | -178.2% |
| Q4 25 | 7.1% | 0.5% | ||
| Q3 25 | 8.3% | 0.8% | ||
| Q2 25 | 5.0% | 1.5% | ||
| Q1 25 | 4.5% | 1.0% | ||
| Q4 24 | 4.5% | 0.1% | ||
| Q3 24 | 4.3% | 1.2% | ||
| Q2 24 | 4.0% | 1.4% | ||
| Q1 24 | 2.4% | 3.0% |
| Q4 25 | 3.48× | — | ||
| Q3 25 | 1.72× | — | ||
| Q2 25 | 2.70× | — | ||
| Q1 25 | -1.29× | — | ||
| Q4 24 | 0.81× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 3.52× | — | ||
| Q1 24 | 0.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
